Ocugen (OCGN) Profit After Tax (2014 - 2026)
Ocugen's (OCGN) quarterly Profit After Tax came in at -$19.2 million in Q1 2026, down 25.02% YoY from -$25.6 million in Q1 2025, and down 8.72% on a QoQ basis from -$17.7 million in Q4 2025.
Ocugen (OCGN) Profit After Tax (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Profit After Tax data on file, last reported at -$19.2 million in Q1 2026.
- Quarterly Profit After Tax fell 25.02% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$71.6 million (down 24.75% YoY) and the FY2025 annual result came in at -$67.8 million, down 25.5% from the prior year.
- Profit After Tax fell to -$19.2 million in Q1 2026, from -$17.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$11.0 million in Q4 2023 to a low of -$23.9 million in Q3 2022.
- A 5-year average of -$17.1 million and a median of -$17.3 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 168.69% — and 2023, when it jumped 51.0%.
- Tracing OCGN's Profit After Tax over 5 years: stood at -$22.4 million in 2022, then surged by 50.89% to -$11.0 million in 2023, then fell by 25.69% to -$13.8 million in 2024, then dropped by 27.73% to -$17.7 million in 2025, then dropped by 8.72% to -$19.2 million in 2026.
- The last three Profit After Tax figures came in at -$19.2 million (Q1 2026), -$17.7 million (Q4 2025), and -$20.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -24.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.90 Mn |
| Mar 31, 2026 | -19.20 Mn |
| Dec 31, 2025 | -17.66 Mn |
| Sep 30, 2025 | -20.05 Mn |
| Jun 30, 2025 | -14.74 Mn |
| Mar 31, 2025 | -15.36 Mn |
| Dec 31, 2024 | -13.83 Mn |
| Sep 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -15.28 Mn |
| Mar 31, 2024 | -11.92 Mn |
| Dec 31, 2023 | -11.00 Mn |
| Sep 30, 2023 | -11.72 Mn |
| Jun 30, 2023 | -23.07 Mn |
| Mar 31, 2023 | -17.33 Mn |
| Dec 31, 2022 | -22.40 Mn |
| Sep 30, 2022 | -23.91 Mn |
| Jun 30, 2022 | -21.48 Mn |
| Mar 31, 2022 | -19.02 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |